431results about How to "Stable expression" patented technology

The invention provides human regulatory molecules and polynucleotides (collectively designated HRM) which identify and encode them. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention further provides methods for diagnosing, preventing, and treating disorders associated with expression of human regulatory molecules.

The invention provides human extracellular adhesive proteins (EXADH) and polynucleotides which identify and encode EXADH. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating or preventing disorders associated with expression of EXADH.

Disclosed is the surprising discovery that aminophospholipids, such as phosphatidylserine and phosphatidylethanolamine, are specific, accessible and stable markers of the luminal surface of tumor blood vessels. The present invention thus provides aminophospholipid-targeted diagnostic and therapeutic constructs for use in tumor intervention. Antibody-therapeutic agent conjugates and constructs that bind to aminophospholipids are particularly provided, as are methods of specifically delivering therapeutic agents, including toxins and coagulants, to the stably-expressed aminophospholipids of tumor blood vessels, thereby inducing thrombosis, necrosis and tumor regression.

The invention provides compositions featuring TRP-4 polypeptides and polynucleotides, methods for expressing such polypeptides and polynucleotides in a cell type of interest, and methods for inducing the activation of the TRP-4 polypeptide in neurons and other cell types using ultrasound.

The invention provides a construction method of a human papilloma virus resistant HPV polyvalent vaccine and application thereof.

The invention is directed to T cells and other cells that express chimeric NK-p30 receptors (“chimeric NKp30 T cells”), methods of making and using chimeric NKp30 T cells, and methods of using these chimeric NKp30 T cells, isolated populations thereof, and compositions comprising the same. In another aspect, said chimeric NKp30 T cells are further designed to express a functional non-TCR receptor. The disclosure also pertains to methods of making said chimeric NKp30 T cells, and methods of reducing or ameliorating, or preventing or treating, diseases and disorders using said chimeric NKp30 T cells, populations thereof, or compositions comprising the same.

The invention provides methods and compositions for localized delivery of a vector comprising a therapeutic agent to a specific region of the brain associated with a neurodegenerative diseases that is characterized by an excess buildup of buildup of intracellular protein aggregates. In particular, the invention provides methods and compositions used to deliver an adeno-associated virus vector (AAV) comprising a nucleotide sequence encoding an inhibitor of apoptosis protein (IAP) to cells in the region.

The invention relates to a double-target CD19 and CD22 chimeric antigen receptor and application thereof, in particular to a polynucleotide sequence which is selected from (1) a coding sequence comprising anti-CD22 and anti-CD19 single-chain antibodies which are connected sequentially, a coding sequence of a human CD8 hinge region, a coding sequence of human CD8 transmembrane region, a coding sequence of a human 41BB intracellular region, a coding sequence of a human CD3 zeta intracellular region and a polynucleotide sequence of a coding sequence of a fragment, comprising an extracellular domain III and a extracellular domain IV, of an optional EGFR; and (2) a complementary sequence of the (1) polynucleotide sequence. The invention further provides a relevant fusion protein, a carrier comprising the coding sequence and application of the fusion protein, the coding sequence and the carrier. The prepared CD19-CD22-BBzCAR-T cell has a strong killing function to the specific tumor cell, CD107a expression and IFN gamma secretion are high, and the killing efficiency to the target cell can reach about 80% under the situation that the effector-target ratio is 10:1.

The invention relates to a method for controlling athetis lepigone pest, which comprises a step of enabling contact between athetis lepigone pest and Cry1A protein. According to the invention, Cry1A protein capable of killing athetis lepigone is generated in a plant body to control the athetis lepigone pest. Compared with the agricultural control method and chemical control method of the prior art, the method provided by the invention protects the full child-bearing period and full plant to control the invasion of the athetis lepigone pest, avoids pollution and residue, realizes a stable and thorough effect, and is simple, convenient and economical.

A single-chain probe of the present invention for detecting a ligand, comprises: a ligand binding protein for binding the ligand; a recognition protein for recognizing that the ligand is bound by the ligand binding protein; and C— and N-terminal fragments, generated by dissecting an enzyme, between the ligand binding protein and the recognition protein, wherein a carboxy terminal end of the C-terminal fragment is located upstream of an amino terminal end of the N-terminal fragment, and the C— and N-terminal fragments vary the enzyme activity via complementation in case where the recognition protein recognizes that the ligand is bound by the ligand binding protein. This makes it possible to achieve detection of a target protein-specific ligand using the single chain with a high efficiency.

A compound having the following formula (II) or its pharmacologically acceptable salt is used as a P2X4 receptor antagonist:in whichR11 represents hydrogen or an alkyl group having 1-8 carbon atoms;R21 represents an alkyl group having 1-8 carbon atoms, an alkoxy group having 1-8 carbon atoms, an alkyl group having 1-8 carbon atoms and having 1-3 halogen substituents, or hydroxyl; andR31 is hydrogen or a halogen atom.

Disclosed herein are compositions and methods of treating and / or correcting ocular disease in a subject, such as a mammal (e.g., human) eye using an Adeno-associated virus (AAV) system. The AAV system employs a nucleic acid encoding a CRISPR-Cas9 system for targeted gene disruption or correction.

The invention discloses gene recombination bacillus amyloliquefaciens and a microbial inoculum preparation method. A bacillus amyloliquefaciens FZB42 strain is taken as a host bacterium to construct the gene recombination bacillus amyloliquefaciens XLV09-1 with transparent vitreoscilla hemoglobin which is regulated and controlled by a P43 strong promoter by contrasting a gene recombination vector. The produced spore number of microbial inoculum prepared by fermenting the bacillus amyloliquefaciens can reach more than 100 hundred millions per milliliter, the overall yield of antibacterial lipopeptid reaches more than 1 gram per liter and prevention effect on various fungal plant diseases is improved by over 30 percent. The microbial inoculum is a green microecological preparation, of no toxic residue, safe to human and livestock, and favorable for protecting the ecological environment.

The invention discloses a recombinant cell line for stable expression of porcine epidemic diarrhea virus S1 protein, a vaccine and an application. The recombinant cell line is constructed by transfecting HEK-293T cells by virtue of recombinant plasmid which is constructed by carrying a target gene on a lentiviral vector, and then transfecting the HEK-293T cells by virtue of generated high-titer virus particles; and the recombinant cell line, which can achieve stable expression, can still keep an excellent protein expression level after several passages. The recombinant cell line for stable expression of the porcine epidemic diarrhea virus S1 protein provided by the invention has the characteristics of being easy for culture, rapid in proliferation, unlimited in expansion, stable in property and high in protein expression amount; and when the vaccine, which is prepared from the expression protein and adjuvants, is used for immunizing pigs, the generation of a high-titer porcine epidemicdiarrhea virus neutralizing antibody can be induced from animal bodies, and the piglets (the pigs) can resist strong attack of porcine epidemic diarrhea viruses.

A nucleic acid encoding a chimeric antigen receptor expressed at surface of a T lymphocyte, said chimeric antigen receptor comprises, connected in the order of, an extracellular binding domain, a transmembrane region, and an intracellular signaling domain, wherein the extracellular binding domain comprises a single chain antibody, scFv(GPC3), which specifically recognizes the C-terminal epitope of GPC3. A genetically modified T lymphocyte having a chimeric antigen receptor expressed at surface thereof, and the chimeric antigen receptor is expressed by the nucleic acid described above.

The invention provides two human S100 proteins designated individually as S100P1 and S10OP2 and collectively as S100P, and polynucleotides which identify and encode S100P. The invention also provides expression vectors, host cells, agonists, antibodies and antagonists. The invention also provides methods for treating disorders associated with expression of S100P.

The invention discloses expression equipment for expressing exogenous protein by secretion in trichoderma reesei cells. The expression equipment comprises the following elements from 5' to 3': (1) an exo-glucan cellobiose hydrolase II promoter of trichoderma reesei; (2) a secretively-expressed signal peptide; (3) a polyclonal locus sequence; and (4) an exo-glucan cellobiose hydrolase II terminator of the trichoderma reesei. Exogenous genes are inserted into the expression equipment, agrobacterium tumefaciens is converted by a T-deoxyribonucleic acid (DNA) binary vector and is jointed with thetrichoderma reesei to obtain trichoderma reesei genetic engineering bacteria which can express heterologous genes from animals, plants, fungi and the like efficiently by secretion, and a large amountof exogenous protein is obtained from the trichoderma reesei genetic engineering bacteria. The trichoderma reesei has an extensive culture condition, and is suitable for solid culture and liquid submerged fermentation; and mycotoxin and antibiotics cannot be generated under the zymogenic condition, and the generated extracellular protein is easy to separate and purify and low in cost.

According to the present invention, there is provided a gene expression vector which is obtained by inserting a gene encoding sarcoglycan into an adeno-associated virus (AAV) vector. By administering the gene expression vector of the present invention to a living body in vivo, a sarcoglycan can be continuously expressed in the living body, so that the restoration of alpha, beta, gamma- and delta-sarcoglycan components can be accompanied and the heart function of the patient of dilated cardiomyopathy can be improved.

A pixel and an organic light emitting display device using the same is provided. The pixel includes an organic light emitting diode (OLED). A pixel circuit controls an amount of current that flows into the OLED. In the pixel, the pixel circuit includes a first transistor controlling an amount of current that flows into a second power source via the OLED from a first power source. A storage capacitor is positioned between a gate electrode of the first transistor and the second power source. A boosting capacitor is positioned between the gate electrode of the first transistor and a boost line.

The invention provides a lentivirus recombinant expression vector / a recombinant lentivirus, as well as application, a host cell and a preparing method thereof. The encoding gene of an estrogen related receptor (ERR) protein can be inserted in a host gene group by the lentivirus recombinant expression vector / the recombinant lentivirus which is provided by the invention through a gene recombinant so as to continuously and stably express the ERR. The ERR can be permanently and stably expressed by the host cell which is provided by the invention, and sufficient high-quality virus liquid can be provided for animal in-vivo experiments. Besides, the lentivirus recombinant expression vector / the recombinant lentivirus which is provided by the invention has a wide host range, can infect various cells, such as nerve cells, muscle cells, liver cells, tumor cells and endothelial cells and has a very wide application range.

A method useful for stable expression of an exogenous gene, introduced into a plant, is provided. By introducing an exogenous gene and 5' upstream sequence of tobacco dehydogenase concurrently, stable expression of the exogenous gene introduced into a plant can be achieved.

The invention discloses a method for producing trehalose synthase by taking integrated recombinant bacillus subtilis as a strain and producing trehalose from the trehalose synthase. The method specifically comprises the following steps of: integrating a trehalose synthase expression element in a bacillus subtilis chromosome to construct integrated recombinant bacillus subtilis, and fermenting in a nutrient culture medium to produce the trehalose synthase by taking the recombinant bacillus subtilis as a strain, wherein via simple separation, the trehalose synthase in the fermentation liquor can be directly used for manufacturing trehalose. The method disclosed by the invention has the advantages that the trehalose synthase is produced by virtue of a food safety expression system, the exogenous gene contained in the strain with integrated expression can be used for stable passage and expression, and the expressed trehalose synthase is secreted to the outside of cells, has no antimicrobial activity, and achieves the requirements of food applications for enzymic preparation, thus being beneficial to further manufacturing for trehalose.

The invention relates to a method for controlling athetis lepigones, which comprises the steps of getting the athetis lepigones to be contacted with protein of CrylF. According to the method, the athetis lepigones are controlled by the protein of CrylF which is capable of killing the athetis lepigones and is generated in a plant. Compared with the agricultural control method and the chemical control method used in the prior art, the method for controlling pests can be used for protecting the whole plant from being damaged by the athetis lepigones in the whole growth period, and the method has the advantages of being pollution-fee, stable in effect, thorough in killing pests, simple, convenient and economic, and having no residue.

The invention relates to the field of genetic engineering, in particular to mutated glucose oxidase with the increased expression quantity and an encoding gene and application thereof. The amino acid sequence of the mutated glucose oxidase is shown as SEQ ID NO.1. The site-specific mutagenesis technology is adopted for carrying out site-specific mutagenesis on a gene (Genebank:FJ979866.1) of glucose oxidase (GOD) of aspergillus niger GIM 3.452(CICC 2377) to enable mutation sites of the amino acid sequence of the mutated glucose oxidase to be Y76C and Q279K; the mutant gene is cloned and connected to a pichia pastoris expression vector pPICZalphaA, and pichia pastoris X33 is converted, and screened to obtain a glucose oxidase pichia pastoris strain P.pastoris X33-pPICZalphaA-GODmut with the increased expression quantity. Enzymatic property determination shows that the mutated glucose oxidase gene can be expressed and inherited in pichia pastoris stably and efficiently, and the enzymatic activity and the stability of glucose oxidase expressed by the strain are remarkably higher than those of an original strain, which lays a good foundation for large-scale production of glucose oxidase.

Improved methods, reagents, and kits for quantitation of HLA-DR and / or CD11b expression on peripheral blood cells are presented. Inclusion of a lysosomotropic amine, such as chloroquine, during staining stabilizes HLA-DR and CD11b expression. Use of a novel anti-CD14 conjugate, anti-CD14-PerCP / CY5.5, permits the ready discrimination of monocytes. The improved methods, reagents, and kits may be used to assess immune competence, and to direct and monitor immunostimulatory therapies in septic patients exhibiting monocyte deactivation.

The invention belongs to the field of microorganism animal cell system, and relates to an establishment method of a fluorescence visualization human hepatoma nude mice model which can self emit high strength red or green fluorescences and has the metastatic ability. After obtaining a human high-metastatic fluorescence hepatoma cell line HCCLM3-R, HCCLM3-G, HCCLM6-R and HCCLM6-G of fluorescence genes with high chromosome conformable degree, high fluorescence intensity and stable expression by using the method of pseudotype slow virus infection, hepatoma cells expressed by the fluorescences is placed beneath nude mice skin to establish a fluorescence visualization high-metastatic human hepatoma nude mice subcutaneous tumor model or subcutaneous fluorescence expression tumor tissues is placed in nude mice hepar to establish a fluorescence visualization high-metastatic human hepatoma nude mice hepar primary tumor model. The got model can be used as a tracer of animal in vivo hepatoma cells, and can be used for molecular mechanism study of hepatoma recurrence and metastatic and prophase therapeutic effect discrimination for new anti-hepatoma therapy and new anti-hepatoma drugs, etc.

The invention discloses a gene of a recombinant staphylococal protein A and application thereof. The nucleotide sequence of the gene of the recombinant staphylococal protein A is shown as SEQ ID NO:1; and the amino acid sequence of the protein coded by the gene is shown as SEQ ID NO:2. The staphylococal protein A is fused with small ubiquitin to form the gene of the recombinant staphylococal protein A; the expressed recombinant protein facilitates purifying the protein and improves the stability and activity of the protein; and experiments prove that the bioactivity of the expressed recombinant staphylococal protein A is not obviously different from that of a natural staphylococal protein A. The recombinant staphylococal protein expression and purification method has the advantages of short production time, high expression efficiency, high expression level, simple purification and the like.

The present invention relates to engineered extra-cellular vesicle internalizing receptors that have the ability to enhance uptake, processing, and presentation to T-cells of tumor-associated antigens by an antigen-presenting cell. It further relates to vectors or antigen presenting cells expressing said receptors, composition and uses thereof for the prevention and / or treatment of a cancer.

Provided herein are compositions and methods for producing milk proteins in plants, which allow for safe, sustainable and humane production of milk proteins for commercial use, such as use in food compositions. The disclosure provides recombinant fusion proteins comprising a milk protein, or fragment thereof and a structured mammalian, avian, plant, or fungal protein, or fragment thereof. The disclosure also provides methods for producing the recombinant fusions proteins, and food compositions comprising the same.

The invention belongs to the field of biomedical genetic engineering and immunology, and particularly relates to a cell strain for expressing African swine fever virus CD2v protein and an applicationof the cell strain. The cell strain for expressing the African swine fever virus CD2v protein, provided by the invention, is obtained by optimizing and synthesizing a nucleic acid sequence of the African swine fever virus CD2v protein, constructing a recombinant lentiviral vector containing an ASFV-CD2v gene, packaging lentivirus, infecting HEK-293T cells and screening. The cell strain for expressing the African swine fever virus CD2v protein provided by the invention has biological characteristics similar to those of parent cells and is beneficial to large-scale production of antigen protein;the expression protein can obtain native conformation and modification processing close to virus protein in expression cells, has good antigenicity, and is easy for mass production.